Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 425

Results For "CENT"

4405 News Found

Kite and Appia Bio collaborate to research and develop Allogeneic cell therapies for cancer
Biotech | August 10, 2021

Kite and Appia Bio collaborate to research and develop Allogeneic cell therapies for cancer

It leverages Kite’s Chimeric Antigen Receptors and Appia Bio’s Allogeneic Cell Technology Platform to Develop Off-the-Shelf Cell Therapies


NRx Pharmaceuticals announces initiation of Phase 2b trial of BriLife vaccine for Covid-19
Drug Approval | August 10, 2021

NRx Pharmaceuticals announces initiation of Phase 2b trial of BriLife vaccine for Covid-19

Preclinical and early human data indicate BriLife may confer enhanced immunity against Delta variant


Govt. to open 10,500 Janaushadhi Kendras: Mandaviya
Healthcare | August 09, 2021

Govt. to open 10,500 Janaushadhi Kendras: Mandaviya

The government has recently enhanced the incentive granted to storeowners from existing Rs. 2.50 lakh to Rs. 5.00 lakh given at the rate of 15% of monthly purchases made, subject to a ceiling of Rs. 15,000 per month


India's doctor-population ratio to reach WHO benchmark soon: Dr Vinod Paul
Healthcare | August 09, 2021

India's doctor-population ratio to reach WHO benchmark soon: Dr Vinod Paul

By 2022, 150,000 primary health care centres would be in place in rural as well as urban areas


China NMPA approves phase II clinical trial of ASC40
Policy | August 09, 2021

China NMPA approves phase II clinical trial of ASC40

Phase II trial will evaluate the safety and efficacy of ASC40 in patients with moderate to severe acne


FDA approves Nexviazyme for late-onset Pompe disease
Drug Approval | August 09, 2021

FDA approves Nexviazyme for late-onset Pompe disease

Nexviazyme specifically targets the M6P receptor, the key pathway for enzyme replacement therapy, to effectively clear glycogen build-up in muscle cells


Strides Pharma reports Q1FY22 consolidated loss at Rs 205.2 Cr
Biotech | August 08, 2021

Strides Pharma reports Q1FY22 consolidated loss at Rs 205.2 Cr

The company expects revenue growth of 10-15 per cent in the US


TAKE divests stake in Navitas Life Sciences to HIG
Biotech | August 08, 2021

TAKE divests stake in Navitas Life Sciences to HIG

The transaction is expected to close in the Q4FY22


We plan to invest Rs. 1,000 Cr in the next 3 to 4 years : Priyanka Chigurupati, Executive Director, Granules Pharmaceuticals
interviews | August 07, 2021

We plan to invest Rs. 1,000 Cr in the next 3 to 4 years : Priyanka Chigurupati, Executive Director, Granules Pharmaceuticals

India is dependent upon China and other countries for a lot of Key Starting Materials (KSM) for their bulk drug needs.


Sanofi to acquire Translate Bio
Biotech | August 07, 2021

Sanofi to acquire Translate Bio

Advances deployment of mRNA technology across vaccines and therapeutics development